These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9801503)

  • 21. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control-relevant erythropoiesis modeling in end-stage renal disease.
    Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
    IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dialysis dose, membrane type, and anemia control.
    Young EW
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S157-60. PubMed ID: 9892384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
    Eschbach JW; Kelly MR; Haley NR; Abels RI; Adamson JW
    N Engl J Med; 1989 Jul; 321(3):158-63. PubMed ID: 2747747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects.
    Abraham PA
    Am J Nephrol; 1990; 10 Suppl 2():7-14. PubMed ID: 2260619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DOQI Guidelines/fifth in a series. A focus on iron management for better HcTs.
    Nephrol News Issues; 1997 Sep; 11(9):39, 53. PubMed ID: 9348872
    [No Abstract]   [Full Text] [Related]  

  • 27. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
    Besarab A; Dalton CL
    Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case study of the anemic patient: epoetin alfa--focus on iron management.
    Kirlin LF
    ANNA J; 1995 Apr; 22(2):192-5. PubMed ID: 7786067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).
    Benz RL; Pressman MR; Hovick ET; Peterson DD
    Am J Kidney Dis; 1999 Dec; 34(6):1089-95. PubMed ID: 10585319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy].
    Wiecek A
    Przegl Lek; 1995; 52(3):93-4. PubMed ID: 7644683
    [No Abstract]   [Full Text] [Related]  

  • 33. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
    Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
    Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health care outcomes case study: anemia in end-stage renal disease.
    Turco TF
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S19-23. PubMed ID: 8846242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron management in ESRD and the role of the nephrology nurse.
    Robbins KC; Senger JM; Kerhulas S; Fishbane S
    ANNA J; 1997 Apr; 24(2):265-72; quiz 273-4. PubMed ID: 9180431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of renal anemia.
    Peco-Antic A
    Turk J Pediatr; 2005; 47 Suppl():19-27. PubMed ID: 15884663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
    Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
    N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
    Suh H; Wadhwa NK
    Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management of renal anemia in 2013].
    Gianella P; Martin PY; Stucker F
    Rev Med Suisse; 2013 Feb; 9(375):462-4, 466-7. PubMed ID: 23539813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythropoietin in pregnancies complicated by severe anemia of renal failure.
    Yankowitz J; Piraino B; Laifer SA; Frassetto L; Gavin L; Kitzmiller JL; Crombleholme W
    Obstet Gynecol; 1992 Sep; 80(3 Pt 2):485-8. PubMed ID: 1495715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.